
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Dr. Bose shares his vision for the future management of patients with intermediate myelofibrosis, including the unmet needs with current treatment options and the emerging data he is closely following.
Case:Â Intermediate-Risk Primary Myelofibrosis in a 68-Year-Old Woman
Clinical Presentation:
PM: No known comorbidities
Initial Clinical Workup and Diagnosis:
Initial Treatments:
